Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s134960
Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering… read more here.
Keywords: profile weekly; efficacy safety; safety profile; dulaglutide ... See more keywords